191 related articles for article (PubMed ID: 38283199)
1. Engineered Exosomes Carrying miR-588 for Treatment of Triple Negative Breast Cancer Through Remodeling the Immunosuppressive Microenvironment.
Zhang Z; Luo X; Xue X; Pang M; Wang X; Yu L; Qian J; Li X; Tian M; Lu A; Lu C; Liu Y
Int J Nanomedicine; 2024; 19():743-758. PubMed ID: 38283199
[TBL] [Abstract][Full Text] [Related]
2. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis.
Yang SJ; Wang DD; Zhong SL; Chen WQ; Wang FL; Zhang J; Xu WX; Xu D; Zhang Q; Li J; Zhang HD; Hou JC; Mao L; Tang JH
Cell Death Dis; 2021 Apr; 12(5):420. PubMed ID: 33911067
[TBL] [Abstract][Full Text] [Related]
5. SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG.
Li K; Lin H; Liu A; Qiu C; Rao Z; Wang Z; Chen S; She X; Zhu S; Li P; Liu L; Wu Q; Wang G; Xu F; Li S
Cancer Lett; 2024 May; 590():216842. PubMed ID: 38582395
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the influence of Human Umbilical Cord Mesenchymal Stem Cells-derived exosomes loaded with miR-3182 on metastatic performance of Triple Negative Breast Cancer cells.
Khazaei-Poul Y; Shojaei S; Koochaki A; Ghanbarian H; Mohammadi-Yeganeh S
Life Sci; 2021 Dec; 286():120015. PubMed ID: 34614416
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
8. [JAG1 affects monocytes-macrophages to reshape the pre-metastatic niche of triple-negative breast cancer through LncRNA MALAT1 in exosomes].
Xu M; Shi Y; Liu J; Wu M; Zhang F; He Z; Tang M
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1525-1535. PubMed ID: 37814867
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic lung cancer cell-derived exosomal miR-21 mediates macrophage M2 polarization and promotes cancer cell proliferation through targeting IRF1.
Jin J; Yu G
World J Surg Oncol; 2022 Jul; 20(1):241. PubMed ID: 35897096
[TBL] [Abstract][Full Text] [Related]
10. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p.
Xing L; Tang X; Wu K; Huang X; Yi Y; Huan J
Aging (Albany NY); 2020 Dec; 13(1):424-436. PubMed ID: 33290256
[TBL] [Abstract][Full Text] [Related]
11. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
Qattan A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
13. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
14. The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.
Kim JE; Kim BG; Jang Y; Kang S; Lee JH; Cho NH
Cancer Lett; 2020 Jan; 469():256-265. PubMed ID: 31672492
[TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from stem cells of human deciduous exfoliated teeth inhibit angiogenesis in vivo and in vitro via the transfer of miR-100-5p and miR-1246.
Liu P; Zhang Q; Mi J; Wang S; Xu Q; Zhuang D; Chen W; Liu C; Zhang L; Guo J; Wu X
Stem Cell Res Ther; 2022 Mar; 13(1):89. PubMed ID: 35241153
[TBL] [Abstract][Full Text] [Related]
16. Adipocyte-derived exosomes promote the progression of triple-negative breast cancer through circCRIM1-dependent OGA activation.
Li Y; Jiang B; Zeng L; Tang Y; Qi X; Wan Z; Feng W; Xie L; He R; Zhu H; Wu Y
Environ Res; 2023 Dec; 239(Pt 1):117266. PubMed ID: 37775001
[TBL] [Abstract][Full Text] [Related]
17. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.
Liang G; Zhu Y; Ali DJ; Tian T; Xu H; Si K; Sun B; Chen B; Xiao Z
J Nanobiotechnology; 2020 Jan; 18(1):10. PubMed ID: 31918721
[TBL] [Abstract][Full Text] [Related]
18. miR-506-loaded gelatin nanospheres target PENK and inactivate the ERK/Fos signaling pathway to suppress triple-negative breast cancer aggressiveness.
Liu XL; Liu WJ; Chen Q; Liu J; Yang CQ; Zhang G; Zhang SL; Guo WH; Li JB; Zhao G; Yin DC; Zhang CY
Mol Carcinog; 2021 Aug; 60(8):538-555. PubMed ID: 34062009
[TBL] [Abstract][Full Text] [Related]
19. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
20. Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells.
Pakravan K; Mossahebi-Mohammadi M; Ghazimoradi MH; Cho WC; Sadeghizadeh M; Babashah S
J Transl Med; 2022 Dec; 20(1):559. PubMed ID: 36463188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
